|
|
5363 N.W. 35th Avenue
Ft. Lauderdale, FL 33309 USA
phone:+1 954 730 0711
fax:+1 954 730 7601
|
|
| Symbol |
Private |
| Founded |
1996 |
| Employees |
400 |
|
|
| www.orbusneich.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Bio-engineered stents and devices for applications in cardiovascular surgery |
|
| Management |
| Al Novak, Chairman of the Board, President, & Chief Executive Officer; Samuel Rasmussen, Assistant to the Chairman; Wayne Johnson, Chief Operating Officer; David Camp, Vice President Corporate Development; Robert Cottone, co-founded |
| |
|
|
| |
|
| Keywords |
| genous, blazer, sapphire, scoreflex, avita |
|
|
|
| Description |
|
OrbusNeich (formed via the merger of Neich Medical and Orbus Medical Technologies in 2005) designs, develops, manufactures, and markets medical devices for the treatment of vascular diseases. |
|
| Products / Services |
OrbusNeich's product portfolio includes the Genous Bio-engineered R stent, an antibody-coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer (TM), R stent (TM), Scoreflex (TM), Sapphire (TM), Sapphire (TM) NC, Avita (TM), Avita HP (TM), SafeCut (TM), Lumina (TM) and Saffron.
|
|
| Technology / Differentiation |
| Unlike drug-eluting stents, which rely upon the pharmacologic inhibition of the bad responses manifest towards the stent, the antibody coated Genous device captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis. |
|
| Market / Customers |
OrbusNeich markets its products to hospitals and private cardiologists. The market for cardiology products is currently $5 billion.
|
|
| Status |
| OrbusNeich's products have received approval for marketing across Asia and Europe. The company is initiating its e-HEALING program, a multi-center, worldwide (outside the United States) prospective registry with 5,000 enrolled patients treated with the Genous Bio-engineered R stent. OrbusNeich is a private company nearing profitability, with sales of $45 million expected by the end of 2008. It is planning an IPO in the United States. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members